BIOBRIEF
Gamma delta T cells, a rare immune subset grown from reprogrammed stem cells, slowed human colorectal tumors in mice — a step toward an off the shelf cancer therapy.
Cancer cell therapy today is largely made one patient at a time. Each treatment is drawn from the patient's own blood, engineered in a clean room, and reinfused at a price most healthcare systems struggle to absorb.
A Kobe University team led by Takashi Aoi reprogrammed adult cells into induced pluripotent stem cells (iPSCs), then turned those iPSCs into gamma-delta T cells, a rare subset that makes up roughly 3 to 5 percent of blood lymphocytes and can recognize cancer without depending on the patient's tissue type. Because the cells come from a donor line, they can be grown in bulk, frozen, and shipped off the shelf.
In a Stem Cell Reports paper published 24 July 2026 and announced by the university, those iPSC-derived gamma-delta T cells suppressed tumor growth in mouse xenograft models carrying patient-derived colorectal cancer tissue. The authors call the result "robust preclinical evidence" rather than a treatment.
The limit is the stage. This is one team's mouse data in a field where solid-tumor xenograft immunotherapy has historically translated poorly to humans. Adicet, GammaDelta Therapeutics, and IN8bio are also chasing off-the-shelf gamma-delta or allogeneic T cell therapies. What Kobe adds is a manufacturing path, not yet a clinical option.